NervGen Pharma Corp. NGEN
1.88 USD +0.25 (+15.34%)
Regular-session close
1.83 -0.05 -2.66%
Pre-market · Nov 16, 8:00 AM ET
1.62 Day range 1.94
1.28 52-week range 6.30
- YTD
- -66.43%
- 1 year
- -23.27%
News
globenewswire.com NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates MIAMI, Nov. 16, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI)…benzinga.com NervGen Says FDA Grants NVG-291 Breakthrough Therapy Designation For Treatment Of Chronic Traumatic Cervical Motor-Incomplete SCI Breakthrough Therapy designation granted based on FDA’s review of safety and efficacy data from the chronic cohort of the Phase 1b/2a CONNECT SCI studyPhase 3 RESTORE registrational study enrolling…
globenewswire.com NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury MIAMI, Nov. 12, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI)…
defenseworld.net NervGen Pharma (NASDAQ:NGEN) Stock Has Consensus Price Target of $14.00 According to Brokerages NervGen Pharma (NASDAQ: NGEN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six research firms that are currently covering the stock, Marketbeat Ratings reports.…
